Pharmacological Profile of Different Berberine Formulations, and Effects on Blood Sugar Levels

Sponsor
Factors Group of Nutritional Companies Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT05370261
Collaborator
(none)
12
1
4
3
4

Study Details

Study Description

Brief Summary

The primary objective of this study is to evaluate the gastrointestinal absorption of berberine (hydrochloride) in a novel formulation in healthy adult volunteers by comparing it with free berberine (hydrochloride) and other formulations. Several pharmacokinetic parameters are compared with those of free berberine and other berberine containing formulations.

As secondary objective, the immediate or short-term effects of Berberine supplementation on blood sugar levels in healthy volunteers are evaluated via a glucose tolerance test (OGTT) using a portable glucometer.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Berberine LipoMicel
  • Dietary Supplement: Regular Berberine soft-gels
  • Dietary Supplement: Regular Berberine hard-gels
  • Dietary Supplement: Dihydroberberine
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
12 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Comparing the Pharmacological Profile of Different Berberine Formulations, and Their Effects on Blood Sugar Levels
Actual Study Start Date :
Feb 1, 2022
Actual Primary Completion Date :
May 4, 2022
Actual Study Completion Date :
May 4, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Berberine LipoMicel soft-gel

Each participant receives their treatment of Berberine LipoMicel soft-gel capsules at a total dose of 500 mg berberine. Treatments are consumed with a glass of water (approx. 200 mL), and standardized breakfast. A standardized lunch is served after the 4hr fasting; standardized dinner after 8hrs. Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours. Samples that are not processed the same day are kept frozen at -20°C until further processing and analysis. Processed samples are analyzed by LC-MS within 24 hours after processing. Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 7 days between each treatment will be used. Adverse events are recorded throughout the study by direct questioning.

Dietary Supplement: Berberine LipoMicel
Berberine LipoMicel® soft-gels. Total dose of 500 mg of berberine

Experimental: Regular Berberine soft-gel

Each participant receives their treatment of regular Berberine soft-gel capsules at a total dose of 500 mg berberine. Treatments are consumed with a glass of water (approx. 200 mL), and standardized breakfast. A standardized lunch is served after the 4hr fasting; standardized dinner after 8hrs. Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours. Samples that are not processed the same day are kept frozen at -20°C until further processing and analysis. Processed samples are analyzed by LC-MS within 24 hours after processing. Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 7 days between each treatment will be used. Adverse events are recorded throughout the study by direct questioning.

Dietary Supplement: Regular Berberine soft-gels
Regular Berberine soft-gels. Total dose of 500 mg of berberine

Experimental: Regular Berberine hard-gel

Each participant receives their treatment of regular Berberine hard-gel capsules at a total dose of 500 mg berberine. Treatments are consumed with a glass of water (approx. 200 mL), and standardized breakfast. A standardized lunch is served after the 4hr fasting; standardized dinner after 8hrs. Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours. Samples that are not processed the same day are kept frozen at -20°C until further processing and analysis. Processed samples are analyzed by LC-MS within 24 hours after processing. Participants are asked to arrive after an overnight fast (at least 9hrs). Each participant acts as their own control; there is no separate control group. A washout period of at least 7 days between each treatment will be used. Adverse events are recorded throughout the study by direct questioning.

Dietary Supplement: Regular Berberine hard-gels
Total dose of 500 mg of berberine

Experimental: Dihydroberberine

Each participant receives their treatment of Dihydroberberine capsules at a total dose of 100 mg of dihydroberberine. Treatments are consumed with a glass of water (approx. 200 mL), and standardized breakfast. A standardized lunch is served after the 4hr fasting; standardized dinner after 8hrs. Capillary whole blood samples are collected at time points 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours.

Dietary Supplement: Dihydroberberine
Total dose of 100 mg of dihydroberberine

Outcome Measures

Primary Outcome Measures

  1. AUC: the area under the concentration-time curve [0 (baseline; pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours (post-dose)]

    To evaluate the gastrointestinal absorption of orally ingested berberine (hydrochloride) in a novel formulation in healthy adult volunteers by comparing the Area under the plasma concentration versus time curve (AUC) with that of with free/regular berberine (hydrochloride).

  2. Cmax: maximum plasma concentration [0 (baseline; pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours (post-dose)]

    To evaluate the gastrointestinal absorption of orally ingested berberine (hydrochloride) in a novel formulation in healthy adult volunteers by comparing the Peak Plasma Concentration (Cmax) with that of with free/regular berberine (hydrochloride).

  3. Tmax: the time point of maximum plasma concentration [0 (baseline; pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours (post-dose)]

    To evaluate the gastrointestinal absorption of orally ingested berberine (hydrochloride) in a novel formulation in healthy adult volunteers by comparing the time point of maximum plasma concentration (Tmax) with that of with free/regular berberine (hydrochloride).

Secondary Outcome Measures

  1. Effects on Blood sugar levels [0 (Baseline; pre-dose), 0.5, 1, 2, 3, and 4 hours (post-dose)]

    To evaluate the immediate or short-term effects of orally ingested Berberine on blood sugar levels in healthy volunteers by using a glucose tolerance test (OGTT).

  2. Changes in Blood sugar concentrations [0 (Baseline; pre-dose), 0.5, 1, 2, 3, and 4 hours (post-dose)]

    To evaluate changes in blood sugar concentrations of orally ingested Berberine in healthy volunteers by using a portable glucometer.

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age 21-65

  • healthy, good physical condition

Exclusion Criteria:
  • Pregnancy or breast-feeding

  • Gastrointestinal conditions

  • Acute or chronic liver disease

  • Acute or chronic kidney disease

  • Acute or chronic cardiovascular disease

  • Hematological disease

  • Diabetes

  • Allergy or Intolerance to gluten

  • Allergy or Intolerance to Berberine

  • Use of any form of nicotine or tobacco

  • Alcohol and substance abuse history

  • Use of medications (e.g., blood sugar-lowering agents, or statins)

  • Use of Berberine supplements

  • Participation in another investigational study

Contacts and Locations

Locations

Site City State Country Postal Code
1 ISURA Burnaby British Columbia Canada V3N4S9

Sponsors and Collaborators

  • Factors Group of Nutritional Companies Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Factors Group of Nutritional Companies Inc.
ClinicalTrials.gov Identifier:
NCT05370261
Other Study ID Numbers:
  • 2021-08-004
First Posted:
May 11, 2022
Last Update Posted:
Jul 13, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Factors Group of Nutritional Companies Inc.

Study Results

No Results Posted as of Jul 13, 2022